Kannalife, a subsidiary of Neuropathix, Inc. (OTCQB: NPTX), is a biopharmaceutical company focused on the research and development of a pipeline of next generation cannabinoid-inspired therapeutics as potent, non-opioid alternatives to treat patients with significant unmet medical needs.
For almost a decade, Kannalife has been a leader in the research, development and discovery of novel Cannabinoid therapeutic agents for targeted drug candidates to treat Chemotherapy Induced Peripheral Neuropathy (CIPN), Hepatic Encephalopathy (HE), Mild Traumatic Brain Injury (mTBI) and chronic pain management. Kannalife has advanced the development of a proprietary product platform of innovative CBD-like molecules for patients with these diseases and other significant medical needs. We have taken a science based, data-driven, validated approach to the discovery and development of novel and promising therapeutic molecules that are similar to CBD.
We are the only company in the cannabinoid therapeutics arena to have licensed the U.S. Government Patent 6,630,507 – “Cannabinoids as Antioxidants and Neuroprotectants”. Our pre-clinical research on cannabidiol (CBD) and understanding of certain mechanism of action, its potential and its limitations, has resulted in our own target drug candidate discovery aimed at improving CBD’s pharmacokinetic and pharmacodynamic (“PK/PD”) aptitude.
In the discovery of KLS-13019 and other patented CBD-like New Chemical Entities (NCE’s), we have made significant improvements in the chemistry efficacy and safety of CBD-like molecules that are up to 200X more potent, 10X more bioavailable, 5X safer and 1000 times more effective than CBD.